Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.
Novo Nordisk (CPSE:NOVO B) has received U.S. FDA Fast Track Designation for coramitug (PRX004) in ATTR amyloidosis with cardiomyopathy.
The company also reported successful pivotal Phase 3 HIBISCUS trial results for etavopivat in sickle cell disease.
These updates expand Novo Nordisk’s late stage pipeline into rare disease areas beyond its established GLP-1 franchise.
Novo Nordisk’s recent news arrives with the shares at DKK263.5 and a mixed return profile, including a 15.3% gain over the past 30 days but a 33.5% decline over the past year. In that context, progress in areas like ATTR amyloidosis and sickle cell disease gives you additional insight into how CPSE:NOVO B is building out its portfolio outside diabetes and obesity.
For investors tracking the stock, these pipeline milestones highlight where future interest could focus if coramitug and etavopivat move closer to approval. The rare disease focus may also matter for how resilient Novo Nordisk’s revenue mix could become over time, given that these areas serve patient groups with limited existing treatment options.
Stay updated on the most important news stories for Novo Nordisk by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novo Nordisk.
CPSE:NOVO B Earnings & Revenue Growth as at Apr 2026
Quick Assessment
✅ Price vs Analyst Target: At DKK263.5, the share price sits about 14% below the DKK307.7 analyst target.
✅ Simply Wall St Valuation: Simply Wall St currently views the shares as undervalued, trading about 65.7% below its DCF based fair value estimate.
✅ Recent Momentum: The stock has gained about 15.3% over the past 30 days.
There is only one way to know the right time to buy, sell or hold Novo Nordisk. Head to Simply Wall St’s company report for the latest analysis of Novo Nordisk’s fair value.
Key Considerations
📊 Fast Track status for coramitug and positive etavopivat data broaden Novo Nordisk’s late stage portfolio into rare diseases alongside its larger franchises.
📊 Monitor how these programs progress toward further Phase 3 data, regulatory filings and any updates on commercial plans or partnering.
⚠️ With 5 flagged risks, including debt and dividend coverage concerns, weigh potential rare disease exposure against the existing financial risk profile.
Dig Deeper
For a fuller picture, including more risks and potential rewards, review the complete Novo Nordisk analysis. You can also visit the community page for Novo Nordisk to see how other investors believe this latest news may affect the company’s narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVO-B.CO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com